LYS228 + Standard of care therapy
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Complicated Urinary Tract Infections
Conditions
Complicated Urinary Tract Infections
Trial Timeline
Oct 19, 2018 → Oct 28, 2019
NCT ID
NCT03377426About LYS228 + Standard of care therapy
LYS228 + Standard of care therapy is a phase 2 stage product being developed by Novartis for Complicated Urinary Tract Infections. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03377426. Target conditions include Complicated Urinary Tract Infections.
What happened to similar drugs?
4 of 20 similar drugs in Complicated Urinary Tract Infections were approved
Approved (4) Terminated (3) Active (15)
🔄HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placeboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03377426 | Phase 2 | Withdrawn |
| NCT03354754 | Phase 2 | Terminated |
Competing Products
20 competing products in Complicated Urinary Tract Infections